<DOC>
	<DOCNO>NCT01934556</DOCNO>
	<brief_summary>The purpose research study determine `` Treat Extend '' regimen ( increase time visit disease stable get bad ) Ranibizumab 0.3 mg injection inside eye safe effective treating patient swell retina diabetes .</brief_summary>
	<brief_title>A Safety Efficacy Trial Treat Extend Protocol Using Ranibizumab With Without Laser Photocoagulation Diabetic Macular Edema</brief_title>
	<detailed_description>This research study compare visual outcome group patient treat monthly injection Ranibizumab 0.3 mg two group patient treat `` Treat Extend '' regimen . One `` Treat Extend '' group also receive laser therapy determine additional beneficial effect .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year age Patient related consideration For sexually active woman childbearing potential , agreement use appropriate form contraception ( abstinence ) duration study Although birth control method 100 % effective , follow consider effective mean contraception : surgical sterilization , use oral contraceptive , barrier contraception use either condom diaphragm spermicidal gel , intrauterine device , contraceptive hormone implant patch . A patient 's primary care physician , obstetrician , gynecologist consult regard appropriate form birth control . Ability willingness return schedule visit assessment Disease relate consideration The presence centerinvolving diabetic macular edema clinical exam SDOCT Best correct visual acuity study eye , use ETDRS testing , 20/25 20/320 ( Snellen equivalent ) , inclusive . Clear ocular medium adequate pupillary dilation permit good quality fundus imaging . General Exclusion Criteria Pregnancy ( positive urine pregnancy test ) lactation . Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD ( Intrauterine Device ) , contraceptive hormone implant patch . Any condition investigator believe would pose significant hazard subject investigational therapy initiate Participation another simultaneous medical investigation trial Ocular Exclusion Criteria Prior Ocular Treatment History active proliferative diabetic retinopathy study eye clinical exam History vitrectomy surgery , submacular surgery , intraocular surgical intervention diabetic macular edema study eye Any previous intravitreal drug delivery ( e.g. , intravitreal corticosteroid injection , antiVEGF drug include ranibizumab , device implantation ) study eye within 90 day screen visit . History prior laser macular photocoagulation 90 day prior screen eligible study inclusion . However , investigator feel additional laser photocoagulation safely perform would benefit patient , eye consideration exclude . Evidence vitreomacular interface abnormality epiretinal membrane may responsible macular edema Concurrent Ocular Conditions • Any concurrent intraocular condition study eye ( e.g. , cataract macular degeneration ) , opinion investigator , could either : Require medical surgical intervention 24month study period prevent treat visual loss might result condition ; allow progress untreated , could likely contribute loss least 2 Snellen equivalent line BCVA ( Best Corrected Visual Acuity ) 24month study period . Active intraocular inflammation ( grade trace ) study eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye Active infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Aphakia absence posterior capsule study eye Intraocular surgery ( include cataract surgery ) study eye within 3 month precede Day 0 Uncontrolled glaucoma study eye ( define IOP ( Intraocular Pressure ) ≥ 30 mmHg despite treatment antiglaucoma medication ) History glaucomafiltering surgery study eye History corneal transplant study eye History par plana vitrectomy Concurrent Systemic Conditions Any history use systemic antiVEGF ( Vascular Endothelial Growth Factor ) agent Uncontrolled blood pressure ( define systolic &gt; 180 mmHg and/or diastolic &gt; 110 mmHg patient sit ) If patient 's initial reading exceeds value , second reading may take 30 minute later . If patient 's blood pressure need control antihypertensive medication , patient become eligible medication take continuously least 30 day prior Day 0 . Atrial fibrillation manage patient 's primary care physician cardiologist within 3 month screen visit Women childbearing potential use adequate contraception ( define inclusion criterion ) . A woman consider childbearing potential postmenopausal , define amenorrhea least 1 year woman &gt; 45 year old ; undergone hysterectomy and/or bilateral oophorectomy . History stroke within last 3 month screen visit History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication Current treatment active systemic infection Active malignancy History allergy fluorescein , amenable treatment Inability obtain fundus photograph fluorescein angiograms sufficient quality analyze grade read center Inability comply study followup procedure Previous participation study investigational drug within 1 month precede Day 0 ( exclude vitamin mineral )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>